Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment

Christina K. Augustine, Yasunori Yoshimoto, Mukur Gupta, Patricia A. Zipfel, M. Angelica Selim, Phillip Febbo, Ann Marie Pendergast, William P. Peters, Douglas S. Tyler

Research output: Contribution to journalArticlepeer-review

86 Scopus citations


Malignant transformation in melanoma is characterized by a phenotype "switch" from E- to N-cadherin, which is associated with increased motility and invasiveness of the tumor and altered signaling, leading to decreased apoptosis. We hypothesized that the novel pentapeptide (ADH-1), which disrupts N-cadherin adhesion, could sensitize melanoma tumors to the cytotoxic effects of chemotherapy. N-cadherin-expressing human melanoma-derived cell lines were used to generate xenografts in animal models to study isolated limb infusion with melphalan and systemic chemotherapy with temozolomide. We report here that melphalan in combination with ADH-1 significantly reduced tumor growth up to 30-fold over melphalan alone. ADH-1 enhancement of response to melphalan was associated with increased formation of DNA adducts, increased apoptosis, and intracellular signaling changes associated with focal adhesions and fibroblast growth factor receptors. Targeted therapy using an N-cadherin antagonist can dramatically augment the antitumor effects of chemotherapy and is a novel approach to optimizing treatment for melanoma.

Original languageEnglish (US)
Pages (from-to)3777-3784
Number of pages8
JournalCancer Research
Issue number10
StatePublished - May 15 2008
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment'. Together they form a unique fingerprint.

Cite this